Clinical Trial Update: Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of CP-690,550 (tofacitinib) in adults with end-stage renal disease on hemodialysis to assess dialysability and drug clearance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• CP-690,550 (tofacitinib) (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: End-Stage Renal Disease, Hemodialysis | Phase 1 | Status: COMPLETED | Results posted: 2012-12-18